Keyphrases
Adjuvant Therapy
17%
Advanced Melanoma
6%
Antitumor Effect
6%
Cancer Patients
8%
Cancer Therapy
9%
Cancer Treatment
15%
Chemotherapy
8%
Clinical Trials
7%
Confidence Interval
5%
Distant Metastasis
6%
Doxorubicin
6%
EORTC
14%
European Organizations
13%
Extremity Soft Tissue Sarcoma
6%
Hazard Ratio
7%
High Dose
8%
High Risk
7%
In Cancer
11%
In-transit Metastasis
6%
Interferon-α (IFN-α)
20%
Interleukin-2
14%
Ipilimumab
9%
Isolated Limb Perfusion
42%
Isolated Perfusion
7%
Locally Advanced
6%
Malignant Melanoma
8%
Melanoma
71%
Melanoma Patients
23%
Melphalan
34%
Metastatic Melanoma
24%
Natural Killer Cells
6%
Overall Survival
13%
Pembrolizumab
9%
Perfusion
12%
Phase II Trial
10%
Placebo
9%
Primary Melanoma
8%
Prognostic Factors
12%
Programmed Death-ligand 1 (PD-L1)
6%
Recurrence-free Survival
6%
Response Rate
6%
Sarcoma
6%
Sentinel Lymph Node
14%
Sentinel Lymph Node Biopsy
8%
Soft Tissue Sarcoma
9%
Stage III Melanoma
10%
Tumor
28%
Tumor Cells
8%
Tumor Necrosis Factor-α
42%
Tumor Response
7%
Medicine and Dentistry
Adjuvant Therapy
13%
Arm
5%
Biopsy Technique
8%
Breast Cancer
7%
Cancer Therapy
8%
Cancer Treatment
12%
Chemotherapy
7%
Clinical Trial
6%
Connective Tissue Cancer
6%
Cutaneous Melanoma
10%
Disease
13%
Hazard Ratio
7%
Immunotherapy
15%
In-Transit Metastasis
5%
Interferon
10%
Ipilimumab
7%
Limb
12%
Limb Perfusion
34%
Malignant Neoplasm
21%
Melanoma
100%
Melphalan
27%
Metastatic Carcinoma
13%
Metastatic Melanoma
12%
Monoclonal Antibody
5%
Neoplasm
44%
Oncology
6%
Overall Survival
13%
Pembrolizumab
9%
Placebo
9%
Prognostic Factor
10%
Recurrence Free Survival
9%
Recurrent Disease
11%
Retroperitoneal Lymph Node Dissection
10%
Sentinel Node
17%
Soft Tissue Sarcoma
11%
Surgery
12%
Tumor Necrosis
6%
Tumor Necrosis Factor
29%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
8%
Clinical Trial
6%
Connective Tissue Cancer
5%
Cytokine
5%
Disease
10%
Doxorubicin
7%
Hyperthermia
5%
Immunotherapy
14%
Interferon
12%
Interleukin 2
7%
Ipilimumab
6%
Limb Perfusion
24%
Liposome
6%
Malignant Neoplasm
37%
Melanoma
65%
Melphalan
20%
Metastatic Melanoma
9%
Neoplasm
44%
Overall Survival
11%
Pembrolizumab
8%
Placebo
9%
Recurrence Free Survival
9%
Recurrent Disease
7%
Soft Tissue Sarcoma
7%
Tumor Necrosis
5%
Tumor Necrosis Factor
27%
